Status:
COMPLETED
Rare CNS Tumors Outcomes &Risk
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
High Grade Meningioma
Ependymoma
Eligibility:
All Genders
18+ years
Brief Summary
Background: Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, accounting for \<2% of all cancers diagnosed in the United States. Some of these t...
Detailed Description
Background: Rare cancers are defined as those with \<40,000 cases per year. There are over 130 separate types of primary CNS tumors, all of which meet the definition of a rare cancer. However, some C...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Participants with rare CNS tumors who meet the following criteria will be invited to participate in the study:
- A diagnosis of rare CNS tumors, (Atypical teratoid rhabdoid tumor (ATRT); Brainstem and midline gliomas; Choroid plexus tumors; Ependymoma; High grade meningioma; Gliomatosis cerebri; Medulloblastoma; Oligodendroglioma / Anaplastic oligodendroglioma; Pineal region tumors; Pleomorphic xanthroastrocytoma / Anaplastic pleomorphic xanthroastrocytoma; PNET (Supratentorial embryonal tumor); Primary CNS sarcoma / Secondary CNS sarcoma (Gliosarcoma) or as reported by the participant:
- Participants who are currently \>= 18 years of age with the initial rare CNS tumor diagnosis occurring at any point in their lifetime are eligible.
- Ability to speak, write, and read English, as questionnaires available in English language only.
- Ability of participant to understand and the willingness to sign a written informed consent document.
- EXCLUSION CRITERIA: See inclusion criteria
Exclusion
Key Trial Info
Start Date :
August 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 6 2025
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT03251989
Start Date
August 21 2017
End Date
May 6 2025
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)/ Neuro-Oncology Branch
Bethesda, Maryland, United States, 20892